(Q36684485)

15 August 2017

1 reference

title

Overview of tumor cell-based vaccines (English)

1 reference

15 August 2017

2

Angus Dalgleish

1 reference

15 August 2017

John Copier

1

1 reference

15 August 2017

publication date

1 September 2006

1 reference

International Reviews of Immunology

15 August 2017

published in

1 reference

15 August 2017

volume

25

1 reference

15 August 2017

issue

5-6

1 reference

15 August 2017

page(s)

297-319

1 reference

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Priming of T cells by exogenous antigen cross-presented on MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Immune surveillance against a solid tumor fails because of immunological ignorance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Tumor immune escape mechanisms: impact of the neuroendocrine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1+-matched situation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Renal cell carcinoma: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Murine interleukin-4 displays potent anti-tumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

The roles of IFN gamma in protection against tumor development and cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Immunological memory induced by genetically transduced tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Cytokine-secreting tumor cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Augmentation of local antitumor immunity in the liver by tumor vaccine modified to secrete murine interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Antitumor and antimetastatic activity of IL-23

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Potent antitumor activity of interleukin-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

The induction of tolerance by dendritic cells that have captured apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

An analysis of autologous T-cell anti-tumour responses in colon-carcinoma patients following active specific immunization (ASI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Combining radiotherapy and immunotherapy: a revived partnership

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992472

10.1080/08830180600992472

21 January 2018

Identifiers

DOI

1 reference

release_unnubd3bobgvnpdcswwizlwdde

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/unnubd3bobgvnpdcswwizlwdde

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference